EQS-News: First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTM
EQS-News: Enlivex Therapeutics, Ltd. First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM 02.12.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. On November 13, Enlivex (NASDAQ: ENLV) announced that th...
United States Shachar Shlosberger Drug Administration Enlivex Therapeutics Ltd Distribution Services Exchange Commission
Source: boersennews.de